Deal date
KANDO id: 750956
Financial Transaction:
Series C-1
Armo BioSciences Inc
Currency
United States Dollar
Value in original currency
67,000,000
Value in USD
67,000,000
Note
"The Series C-1 proceeds will be used to initiate phase 2/3 studies with ARMO’s lead immunotherapy agent AM0010 in non-small cell lung cancer and renal cell cancer and to support an ongoing pivotal phase 3 clinical trial in advanced pancreatic cancer. The
Lead investor
| Investor | Country | Notes | |
|---|---|---|---|
|
Qiming Venture Partners |
China | Initial investment. |
Round participants
| Investor | Country | Notes | |
|---|---|---|---|
![[current-page:title] logo](/sites/default/files/styles/icon/public/default_images/_no-logo.png?itok=AH4pbDYM){kind=icon}
|
Celgene CorpBiopharmaceutical company committed to improving the lives of patients worldwide. |
United States | Follow-on investment. |
|
|
Clough Capital Partners LP |
Follow-on investment. | |
|
Decheng Capital(德诚资本) |
Initial investment. | |
|
Duff Ackerman & Goodrich Ventures(DAG Ventures)A mid-stage venture capital partnership with a service-oriented mindset. |
United States | Follow-on investment. |
|
GV.The venture capital arm of Alphabet Inc. (Formerly Google Ventures.) |
United States | Follow-on investment. |
|
|
HBM Healthcare Investments |
Follow-on investment. | |
|
Kleiner Perkins Caufield & Byers LLC(KPCB)Venture capital firm. |
United States | Follow-on investment. |
|
NanoDimension Inc(ND Capital) |
United States | Follow-on investment. |
|
OrbiMed Advisors LLCAmerican investment firm focused on making public and private investments in the healthcare and biotechnology industries. |
United States | Follow-on investment. |
|
Quan Capital LtdAlternative investment firm with a focus on control-oriented investments in small- and medium-sized enterprises. |
Initial investment. | |
|
|
RTW Investments |
Initial investment. | |
|
Sequoia Capital Operations LLC(Sequoia)Venture capital firm. |
United States | Initial investment. |